Abstract
This article submitted to the journal CNS & Neurological Disorders - Drug Targets has been withdrawn upon the request of the author due to the errors and invalid information in the article.
Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.
The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php
BENTHAM SCIENCE DISCLAIMER:
It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.
CNS & Neurological Disorders - Drug Targets
Title:Withdrawal Notice: Comparison of Pharmaceutical Effect of Alemtuzumab and Natalizumab and Their Side Effects in Treatment of Various Stages of Multiple Sclerosis Patients
Volume: 20
Author(s): Mostafa Mohammadi*
Affiliation:
- Islamic Azad University of Central Tehran Branch, Department of Electrical Engineering, Tehran,Iran
Abstract: This article submitted to the journal CNS & Neurological Disorders - Drug Targets has been withdrawn upon the request of the author due to the errors and invalid information in the article.
Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.
The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php
BENTHAM SCIENCE DISCLAIMER:
It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.
Export Options
About this article
Cite this article as:
Mohammadi Mostafa*, Withdrawal Notice: Comparison of Pharmaceutical Effect of Alemtuzumab and Natalizumab and Their Side Effects in Treatment of Various Stages of Multiple Sclerosis Patients, CNS & Neurological Disorders - Drug Targets 2021; 20 () . https://dx.doi.org/10.2174/1871527320666210129121701
DOI https://dx.doi.org/10.2174/1871527320666210129121701 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Heart and Brain Axis Targets in CNS Neurological Disorders
Recently there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system (CNS) neurological disorders. The purpose ...read more
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities
The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive ...read more
Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches
Emerging evidence suggests that glial cells may play a pivotal role in neuroanatomical and behavioral changes found in autism spectrum disorder (ASD). Many individuals with ASD experience a neuro-immune system abnormalities throughout life, which implicates a potential role of microglia in the pathogenesis of ASD. Dysfunctional astrocytes and oligodendrocytes were ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Current Pharmaceutical Design Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic:Active and Passive Aβ-Immunotherapy: Preclinical and Clinical Studies and Future Directions: Part I (Guest Editors: Michael G. Agadjanyan and David H. Cribbs)]
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: MiRNAcles in the Brain: What to Wish and What to Fear)
CNS & Neurological Disorders - Drug Targets Generating Recombinant Antibodies for Research, Diagnostics and Therapy Using Phage Display
Current Biotechnology The Use of Lectins as Tools to Combat SARS-CoV-2
Current Pharmaceutical Design Delineating Somatostatins Neuronal Actions
Current Drug Targets - CNS & Neurological Disorders Modulation of Immunity and the Inflammatory Response: A New Target for Treating Drug-resistant Epilepsy
Current Neuropharmacology Relation between Apolipoprotein E in Alzheimer’s Disease and SARS-CoV-2 and their Treatment Strategy: A Review
CNS & Neurological Disorders - Drug Targets Overview on the Tricks of HIV Tat to Hit the Blood Brain Barrier
Current HIV Research Photosensitizers Mediated Photodynamic Inactivation Against Virus Particles
Mini-Reviews in Medicinal Chemistry The Critical Role of Toll-Like Receptor Signaling Pathways in the Induction and Progression of Autoimmune Diseases
Current Molecular Medicine Subunit Protein Vaccines: Theoretical and Practical Considerations for HIV-1
Current Molecular Medicine The Genetic Basis of Human Cytomegalovirus Resistance and Current Trends in Antiviral Resistance Analysis
Infectious Disorders - Drug Targets Neural Progenitors and HIV-1- Associated Central Nervous System Disease in Adults and Children
Current HIV Research Astragaloside IV Supplementation Promotes A Neuroprotective Effect in Experimental Models of Neurological Disorders: A Systematic Review
Current Neuropharmacology Acyclovir in the Treatment of Herpes Viruses – A Review
Current Medicinal Chemistry Large-Scale Production Means for the Manufacturing of Lentiviral Vectors
Current Gene Therapy Assessing Activation States in Microglia
CNS & Neurological Disorders - Drug Targets Pan-Vertebrate Toll-Like Receptors During Evolution
Current Genomics